Perceptive Advisors LLC sold $183k of LYRA
owner at Lyra Therapeutics, Inc.. 45,875 shares at an average of $3.98, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +12Role10% owner
- +12Trade size$183k at market
- +10Share of holdings soldSold 28% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.8%, 3m -65.4%, 6m -80.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-280481, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -4,783 | $4.31 | $21k | 161,318 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -537 | $4.31 | $2,317 | 18,122 | Nov 13, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -7,862 | $4.06 | $32k | 153,456 | Nov 13, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -883 | $4.06 | $3,584 | 17,239 | Nov 13, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -28,597 | $3.90 | $112k | 124,859 | Nov 13, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -3,213 | $3.90 | $13k | 14,026 | Nov 13, 2025 |
Related signals
Other insiders at Lyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $2,587 769 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $5,726 1,702 shares | -0% | |
| 37Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $344k 70,390 shares | -31% | |
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $6,094 684 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $14k 1,565 shares | -0% | |
| 39Weak | LYRAbuy Lyra Therapeutics, Inc. | Harlan Waksal Executive Chair | $74k 25,000 shares | +11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.